Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?

Franco R, Rocco G, Marino FZ, Pirozzi G, Normanno N, Morabito A, Sperlongano P, Stiuso P, Luce A, Botti G, Caraglia M.

Expert Rev Anticancer Ther. 2013 Apr;13(4):407-20. doi: 10.1586/era.13.18. Review.

PMID:
23560836
2.

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.

3.
4.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
5.

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.

Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, Yagi Y, Mark EJ, Iafrate AJ, Mino-Kenudson M.

Mod Pathol. 2012 Nov;25(11):1462-72. doi: 10.1038/modpathol.2012.109. Epub 2012 Jun 29.

6.

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA.

Mol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27.

7.

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

Dagogo-Jack I, Shaw AT, Riely GJ.

Clin Pharmacol Ther. 2017 May;101(5):625-633. doi: 10.1002/cpt.653. Epub 2017 Mar 17. Review.

PMID:
28182271
8.

Targeting oncogenic ALK: a promising strategy for cancer treatment.

Grande E, Bolós MV, Arriola E.

Mol Cancer Ther. 2011 Apr;10(4):569-79. doi: 10.1158/1535-7163.MCT-10-0615. Review. Erratum in: Mol Cancer Ther. 2011 Aug;10(8):1529.

9.

ALK-immunoreactive neoplasms.

Minoo P, Wang HY.

Int J Clin Exp Pathol. 2012;5(5):397-410. Epub 2012 May 23. Review.

10.

Anaplastic lymphoma kinase as a therapeutic target.

Kruczynski A, Delsol G, Laurent C, Brousset P, Lamant L.

Expert Opin Ther Targets. 2012 Nov;16(11):1127-38. doi: 10.1517/14728222.2012.719498. Epub 2012 Sep 24. Review.

PMID:
22998583
11.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
12.

The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.

D'Arcangelo M, Wynes MW, Hirsch FR.

Curr Opin Oncol. 2013 Mar;25(2):121-9. doi: 10.1097/CCO.0b013e32835d8175. Review.

PMID:
23385859
13.

Virtual screening and further development of novel ALK inhibitors.

Okamoto M, Kojima H, Saito N, Okabe T, Masuda Y, Furuya T, Nagano T.

Bioorg Med Chem. 2011 May 15;19(10):3086-95. doi: 10.1016/j.bmc.2011.04.008. Epub 2011 Apr 7.

PMID:
21515061
14.

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Ahn HK, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K.

Lung Cancer. 2012 May;76(2):253-4. doi: 10.1016/j.lungcan.2012.02.003. Epub 2012 Mar 3.

PMID:
22385925
15.

Targeted therapy for NSCLC: ALK inhibition.

Pearson R, Kolesar JM.

J Oncol Pharm Pract. 2012 Jun;18(2):271-4. doi: 10.1177/1078155211417477. Epub 2011 Aug 15. Review.

PMID:
21844131
16.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

17.

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.

Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, Martinez-Marti A, Tallada N, Murtra-Garrell N, Navarro-Mendivill A, Rodriguez-Freixinos V, Canela M, Ramon y Cajal S, Felip E.

PLoS One. 2013;8(1):e52261. doi: 10.1371/journal.pone.0052261. Epub 2013 Jan 24.

18.
19.

Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.

Latif M, Saeed A, Kim SH.

Arch Pharm Res. 2013 Sep;36(9):1051-4. doi: 10.1007/s12272-013-0157-8. Epub 2013 May 23. Review.

PMID:
23700294
20.

Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases.

Kim H, Xu X, Yoo SB, Sun PL, Jin Y, Paik JH, Choe G, Jheon S, Lee CT, Chung JH.

Histopathology. 2013 Jan;62(2):305-14. doi: 10.1111/j.1365-2559.2012.04356.x. Epub 2012 Sep 28.

PMID:
23020707

Supplemental Content

Support Center